Day One Biopharmaceuticals Inc (NASDAQ:DAWN) saw an upside of 3.00% to close Friday at $13.38 after adding $0.39 on the day. The 5-day average trading volume is 852,180 shares of the company’s common stock. It has gained $14.52 in the past week and touched a new high 1 time within the past 5 days. An average of 910,000 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 736,880.
DAWN’s 1-month performance is -0.96% or -$0.35 on its low of $12.72 reached on 09/21/23. The company’s shares have touched a 52-week low of $10.84 and high of $25.77, with the stock’s rally to the 52-week high happening on 01/09/23. YTD, DAWN has lost -37.83% or -$8.14 and has reached a new high 2 times. However, the current price is down -48.08% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DAWN stock investors last saw insider trading activity on Aug 17.Bender Jeremy (Chief Executive Officer) most recently sold 2,996 shares at $13.86 per share on Aug 17. This transaction cost the insider $41,525. COO, CFO and Secretary, York Charles N II, sold 922 shares at a price of $13.86 on Aug 17. Then, on Aug 17, Head of Research and Developme Blackman Samuel C. sold 668 shares at a price of $13.86 per share. This transaction amounted to $9,258.
Valuation Metrics
DAWN stock has a beta of -1.93. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.73.
Day One Biopharmaceuticals Inc’s quick ratio for the recent period was 18.35, with the current ratio over the same period at 18.35. The firm’s gross profit as reported stood at -$4.75 million against revenue of $146.91 million.
Earnings Surprise
Net income and sales went up compared to those figures reported in the previous quarter. EBITDA for the quarter stood at more than -$49.16 million. DAWN stock balance sheet for the recent quarter shows that total liabilities totaled 24.7 million, with total debt at $0.62 million. Shareholders hold equity totaling $86.97 million.
Let’s look briefly at Day One Biopharmaceuticals Inc (DAWN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 40.99% to suggest the stock is trending Neutral, with historical volatility in this time period at 50.01%.
The stock’s 5-day moving average is $13.52, reflecting a -3.88% or -$0.54 change from its current price. DAWN is currently trading -3.88% above its 20-day SMA, -7.53% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +12.15% and SMA200 by-37.62%.
Stochastic %K and %D was 13.17% and 19.62% and the average true range (ATR) pointed at 0.65. The RSI (14) points at 45.08%, while the 14-day stochastic is at 25.00% with the period’s ATR at 0.64. The stock’s 9-day MACD Oscillator is pointing at -0.81 and -0.89 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Day One Biopharmaceuticals Inc (NASDAQ: DAWN), BofA Securities downgraded it to an Underperform rating. They previously had a Buy rating on the stock. Analysts offering their rating for DAWN stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate DAWN as a “sell,”, while 1 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 8 have offered a “buy” rating.
What is DAWN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $9.00 and a high of $54.00, with their median price target at $40.00. Looking at these predictions, the average price target given by analysts is for Day One Biopharmaceuticals Inc (DAWN) stock is $38.78.
